Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 2
2011 1
2012 5
2013 8
2014 10
2015 12
2016 19
2017 18
2018 16
2019 14
2020 13
2021 14
2022 9
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30819101

131 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).
Pasquau J, de Jesus SE, Arazo P, Crusells MJ, Ríos MJ, Lozano F, de la Torre J, Galindo MJ, Carmena J, Santos J, Tornero C, Verdejo G, Samperiz G, Palacios Z, Hidalgo-Tenorio C; RIDAR Study Group. Pasquau J, et al. BMC Infect Dis. 2019 Feb 28;19(1):207. doi: 10.1186/s12879-019-3817-6. BMC Infect Dis. 2019. PMID: 30819101 Free PMC article.
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group. Troya J, et al. PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. PLoS One. 2016. PMID: 27727331 Free PMC article.
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation.
Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S. Di Cristo V, et al. HIV Res Clin Pract. 2020 Feb;21(1):34-43. doi: 10.1080/25787489.2020.1734752. Epub 2020 Mar 4. HIV Res Clin Pract. 2020. PMID: 32129161 Clinical Trial.
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D, Gayet-Ageron A, Battegay M, Cavassini M, Fehr J, Hirzel C, Schmid P, Bernasconi E, Calmy A; Swiss HIV Cohort Study. Sculier D, et al. BMC Infect Dis. 2017 Jul 6;17(1):476. doi: 10.1186/s12879-017-2579-2. BMC Infect Dis. 2017. PMID: 28683720 Free PMC article. Clinical Trial.
131 results